Novel approaches for identification of broadly cross-reactive HIV-1 neutralizing human monoclonal antibodies and improvement of their potency

Current Pharmaceutical Design

Volumn 13, Issue 2, 2007, Pages 203-212

  Zhang, Mei Yun ^a,b   Dimitrov, Dimiter S ^a  

^a CCRNP   (United States)

^b SAIC FREDERICK INC   (United States)

Author keywords

AIDS; Antibodies; gp120; gp41; HIV; Inhibitors; Vaccines

Indexed keywords

EPITOPE; GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 41; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; HUMAN MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 17B; MONOCLONAL ANTIBODY 2F5; MONOCLONAL ANTIBODY 4E10; MONOCLONAL ANTIBODY B12; MONOCLONAL ANTIBODY M14; MONOCLONAL ANTIBODY M18; MONOCLONAL ANTIBODY M43; MONOCLONAL ANTIBODY M44; MONOCLONAL ANTIBODY M45; MONOCLONAL ANTIBODY M47; MONOCLONAL ANTIBODY M48; MONOCLONAL ANTIBODY X5; MONOCLONAL ANTIBODY Z13; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANTIBODY DETECTION; ANTIGEN BINDING; CONCENTRATION RESPONSE; CROSS REACTION; CRYSTAL STRUCTURE; DRUG DESIGN; DRUG POTENCY; EXPOSURE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNE RESPONSE; IN VIVO STUDY; MOLECULAR INTERACTION; NONHUMAN; PRIORITY JOURNAL; REVIEW; VIRUS ISOLATION; VIRUS NEUTRALIZATION;

ANIMALS; ANTIBODIES, MONOCLONAL; CROSS REACTIONS; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP41; HIV-1; HUMANS; NEUTRALIZATION TESTS;

EID: 33846175669     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161207779313669     Document Type: Review

References (62)

1. McMichael AJ, Hanke T. HIV vaccines 1983-2003. Nat Med 2003; 9: 874-880.
2. Burton DR. Antibodies, viruses and vaccines. Nat Rev Immunol 2002; 2: 706-713.
3. Wei X, Decker JM, Wang S, Hui H, Kappes JC, Wu X, et al. Antibody neutralization and escape by HIV-1. Nature 2003; 422: 307-312.
4. Richman DD, Wrin T, Little SJ, Petropoulos CJ. Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc Natl Acad Sci USA 2003; 100: 4144-4149.
5. Garber DA, Silvestri G, Feinberg MB. Prospects for an AIDS vaccine: three big questions, no easy answers. Lancet Infect Dis 2004; 4: 397-413.
6. Kwong PD, Doyle ML, Casper DJ, Cicala C, Leavitt SA, Majeed S, et al. HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites. Nature 2002; 420: 678-682.
7. Burton DR, Montefiori DC. The antibody response in HIV-1 infection. AIDS 1997; 11(Suppl A): S87-S98.
8. Ferrantelli F, Ruprecht RM. Neutralizing antibodies against HIV-back in the major leagues? Curr Opin Immunol 2002; 14: 495-502.
9. Veazey RS, Shattock RJ, Pope M, Kirijan JC, Jones J, Hu Q, et al. Prevention of virus transmission to macaque monkeys by a vaginally applied monoclonal antibody to HIV-1 gp120. Nat Med 2003; 9: 343-346.
10. Armbruster C, Stiegler GM, Vcelar BA, Jager W, Michael NL, Vetter N, et al. A phase I trial with two human monoclonal anti-bodies (hMAb 2F5, 2G12) against HIV-1. AIDS 2002; 16: 227-233.
11. Stiegler G, Annbruster C, Vcelar B, Stoiber H, Kunert R, Michael NL, et al. Antiviral activity of the neutralizing antibodies 2F5 and 2G12 in asymptomatic HIV-1-infected humans: a phase I evaluation. AIDS 2002; 16: 2019-2025.
12. Haynes BF, Fleming J, St Clair WE, Katinger H, Stiegler G, Kunert R, et al. Cardiolipin Polyspecific Autoreactivity in Two Broadly Neutralizing HIV-1 Antibodies. Science 2005; 308: 1906-8.
13. Gorny MK, Gianakakos V, Sharpe S, Zolla-Pazner S. Generation of human monoclonal antibodies to human immunodeficiency virus. Proc Natl Acad Sci USA 1989; 86: 1624-1628.
14. Robinson JE, Holton D, Pacheco-Morell S, Liu J, McMurdo H. Identification of conserved and variant epitopes of human immunodeficiency virus type 1 (HIV-1) gp120 by human monoclonal antibodies produced by EBV-transformed cell lines. AIDS Res Hum Retroviruses 1990; 6: 567-579.
15. Grunow R, Jahn S, Porstmann T, Kiessig SS, Steinkellner H, Steindl F, et al. The high efficiency, human B cell immortalizing heteromyeloma CB-F7. Production of human monoclonal antibodies to human immunodeficiency virus. J Immunol Methods 1988; 106: 257-265.
16. Buchacher A, Predl R, Strutzenberger K, Steinfellner W, Trkola A, Purtscher M, et al. Generation of human monoclonal antibodies against HIV-1 proteins; electrofusion and Epstein-Barr virus transformation for peripheral blood lymphocyte immortalization. AIDS Res Hum Retroviruses 1994; 10: 359-369.
17. Gorny MK, Xu JY, Gianakakos V, Karwowska S, Williams C, Sheppard HW, et al. Production of site-selected neutralizing human monoclonal antibodies against the third variable domain of the human immunodeficiency virus type 1 envelope glycoprotein. Proc Natl Acad Sci USA 1991; 88: 3238-3242.
18. Posner MR, Elboim H, Santos D. The construction and use of a human-mouse myeloma analogue suitable for the routine production of hybridomas secreting human monoclonal antibodies. Hybridoma 1987; 6: 611-625.
19. Posner MR, Hideshima T, Cannon T, Mukherjee M, Mayer KH, Byrn RA. An IgG human monoclonal antibody that reacts with HIV-1/GP120, inhibits virus binding to cells, and neutralizes infection. J Immunol 1991; 146: 4325-4332.
20. Barbas CF, Burton DR, Scott JK, Silverman GJ. Phage Display: A Laboratory Mannual. Cold Spring Harbor: Cold Spring Harbor Laboratory Press, 2001.
21. Burton DR, Barbas CF, Persson MA, Koenig S, Chanock RM, Lerner RA. A large array of human monoclonal antibodies to type 1 human immunodeficiency virus from combinatorial libraries of asymptomatic seropositive individuals. Proc Natl Acad Sci USA 1991; 88: 10134-10137.
22. Zhang MY, Shu Y, Phogat S, Xiao X, Cham F, Bouma P, et al. Broadly cross-reactive HIV neutralizing human monoclonal antibody Fab selected by sequential antigen panning of a phage display library. J Immunol Methods 2003; 283: 17-25.
23. Muster T, Steindl F, Purtscher M, Trkola A, Klima A, Himmler G, et al. A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. J Virol 1993; 67: 6642-6647.
24. Stiegler G, Kunert R, Purtscher M, Wolbank S, Voglauer R, Steindl F, et al. A potent cross-clade neutralizing human monoclonal antibody against a novel epitope on gp41 of human immunodeficiency virus type 1. AIDS Res Hum Retroviruses 2001; 17: 1757-1765.
25. Gorny MK, Conley AJ, Karwowska S, Buchbinder A, Xu JY, Emini EA, et al. Neutralization of diverse human immunodeficiency virus type 1 variants by an anti-V3 human monoclonal antibody. J Virol 1992; 66: 7538-7542.
26. Sanders RW, Venturi M, Schiffner L, Kalyanaraman R, Katinger H, Lloyd KO, et al. The mannose-dependent epitope for neutralizing antibody 2G12 on human immunodeficiency virus type 1 glycoprotein gp120. J Virol 2002; 76: 7293-7305.
27. Scanlan CN, Pantophlet R, Wormald MR, Ollmann SE, Stanfield R, Wilson IA, et al. The broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2G12 recognizes a cluster of alpha1←2 mannose residues on the outer face of gp120. J Virol 2002; 76: 7306-7321.
28. Trkola A, Purtscher M, Muster T, Ballaun.C, Buchacher A, Sullivan N, et al. Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. J Virol 1996; 70: 1100-1108.
29. Burton DR, Pyati J, Koduri R, Sharp SJ, Thornton GB, Parren PW et al. Efficient neutralization of primary isolates of HIV-1 by a recombinant human monoclonal antibody. Science 1994; 266: 1024-1027.
30. Roben P, Moore JP, Thali M, Sodroski J, Barbas CF 3rd, Burton DR. Recognition properties of a panel of human recombinant Fab fragments to the CD4 binding site of gp120 that show differing abilities to neutralize human immunodeficiency virus type 1. J Virol 1994; 68: 4821-4828.
31. Zwick MB, Labrijn AF, Wang M, Spenlehauer C, Saphire EO, Binley JM, et al. Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodeficiency virus type 1 glycoprotein gp41. J Virol 2001; 75: 10892-10905.
32. Davis CG, Jia XC, Feng X, Haak-Frendscho M. Production of human antibodies from transgenic, mice. Methods Mol Biol 2004; 248: 191-200.
33. Okada N, Yin S, Asai S, Kimbara N, Dohi N, Hosokawa M, et al. Human IgM Monoclonal Antibodies Reactive with HIV-1-Infected Cells Generated Using a Trans-Chromosome Mouse. Microbiol Immunol 2005; 49: 447-459.
34. Moulard. M, Phogat SK, Shu Y, Labrijn AF, Xiao X, Binley JM, et al. Broadly cross-reactive HIV-1-neutralizing human monoclonal Fab selected for binding to gp120-CD4-CCR5 complexes. Proc Natl Acad Sci USA 2002; 99: 6913-6918.
35. Chow YH, Wei OL, Phogat S, Sidorov IA, Fouts TR, Broder CC, et al. Conserved structures exposed in HIV-1 envelope glycoproteins stabilized by flexible linkers as potent entry inhibitors and potential immunogens. Biochemistry 2002; 41: 7176-7182.
36. Montefiori DC, Pantaleo G, Fink LM, Zhou JT, Zhou JY, Bilska M, et al. Neutralizing and infection-enhancing antibody responses to human immunodeficiency virus type 1 in long-term nonprogressors. J Infect Dis 1996; 173: 60-67.
37. Dimitrov DS. Fusin - a place for HIV-1 and T4 cells to meet. Nat Med 1996; 2: 640-641.
38. Lapham CK, Ouyang J, Chandrasekhar B, Nguyen NY, Dimitrov DS, Golding H. Evidence for cell-surface association between fusin and the CD4-gp120 complex in human cell lines. Science 1996; 274: 602-605.
39. Jones PL, Korte T, Blumenthal R. Conformationl changes in cell surface HIV-1 envelope glycoproteins are triggered by cooperation between cell surface CD4 and co-receptors. J Biol Chem 1998; 273: 404-409.
40. Devico, A, Silver A, Thronton AM, Sarngadharan MG, Pal R. Covalently crosslinked complexes of human immunodeficiency virus type 1 (HIV-1) gp120 and CD4 receptor elicit a neutralizing immune response that includes antibodies selective for primary virus isolates. Virology 1996; 218: 258-263.
41. Fouts T, Godfrey Y, Bobb K, Montefiori D, Hanson CV, Kalyanaraman VS, et al. Crosslinked HIV-1 envelope-CD4 receptor complexes elicit broadly cross- reactive neutralizing antibodies in rhesus macaques. Proc Natl Acad Sci USA 2002; 99: 11842-11847.
42. Xiao, X, Phogat S, Shu Y, Phogat A, Chow YH, Wei OL, et al. Purified complexes of HIV-1 envelope glycoproteins with CD4 and CCR5(CXCR4): production, characterization and immunogenicity. Vaccine 2003; 21: 4275-4284.
43. Darbha R, Phogat S, Labrijn AF, Shu Y, Gu Y, Andrykovitch M, et al. Crystal structure of the broadly cross-reactive HIV-1-neutralizing Fab X5 and fine mapping of its epitope. Biochemistry 2004; 43: 1410-1417.
44. Huang CC, Tang M, Zhang MY, Majeed S, Montabana E, Stanfield RL, et al. Structure of a V3-containing HIV-1 gp120 core. Science 2005; 310: 1025-1028.
45. Zhang MY, Shu Y, Rudolph D, Prabakaran P, Labrijn AF, Zwick MB, et al. Improved breadth and potency of an HIV-1-neutralizing human single-chain antibody by random mutagenesis and sequential antigen panning. J Mol Biol 2004; 335: 209-219.
46. Bures R, Morris L, Williamson C, Ramjee G, Deers M, Fiscus SA, et al. Regional clustering of shared neutralization determinants on primary isolates of clade C human immunodeficiency virus type 1 from South Africa. J Virol 2002; 76: 2233-2244.
47. Labrijn AF, Poignard P, Raja A, Zwick MB, Delgado K, Franti M, et al. Access of antibody molecules to the conserved coreceptor binding site on glycoprotein gp120 is sterically restricted on primary human immunodeficiency virus type 1. J Virol 2003; 77: 10557-10565.
48. Decker JM, Bibollet-Ruche F, Wei X, Wang S, Levy DN, Wang W, et al. Antigenic conservation and immunogenicity of the HIV coreceptor binding site. J Exp Med 2005; 201: 1407-1419.
49. Quinnan GV, Zhang PF, Fu DW, Dong M, Alter HJ. Expression and characterization of HIV type 1 envelope protein associated with a broadly reactive neutralizing antibody response. AIDS Res Hum Retroviruses 1999; 15: 561-570.
50. Zhang PF, Bouma P, Park EJ, Margolick JB, Robinson JE, Zolla-Pazner S, et al. A variable region 3 (V3) mutation determines a global neutralization phenotype and CD4-independent infectivity of a human immunodeficiency virus type 1 envelope associated with a broadly cross-reactive, primary virus-neutralizing antibody response. J Virol 2002; 76: 644-655.
51. Quinnan GV, Jr., Yu XF, Lewis MG, Zhang PF, Sutter G, Silvera P, et al. Protection of rhesus monkeys against infection with minimally pathogenic simian-human immunodeficiency virus: correlations with neutralizing antibodies and cytotoxic T cells. J Virol 2005; 79: 3358-3369.
52. Zhang MY, Xiao X, Sidorov IA, Choudhry V, Cham F, Zhang PF, et al. Identification and characterization of a new cross-reactive human immunodeficiency virus type 1-neutralizing human monoclonal antibody. J Virol 2004; 78: 9233-9242.
53. Prabakaran P, Gan JH, Wu YQ, Zhang MY, Dimitrov DS, and Ji X. Structural Mimicry of CD4 by a cross-Reactive HIV-1 Neutralizing Antibody with CDR-H2 and H3 Containing Unique Motifs. J Mol Biol 2006; 357: 82-99.
54. Martin L, Stricher F, Misse D, Sironi F, Pugniere M, Barthe P, et al. Rational design of a CD4 mimic that inhibits HIV-1 entry and exposes cryptic neutralization epitopes. Nat Biotechnol 2003; 21: 71-76.
55. Zhang MY, Shu Y, Sidorov I, Dimitrov DS. Identification of a novel CD4i human monoclonal antibody Fab that neutralizes HIV-1 primary isolates from different clades. Antiviral Res 2004; 61: 161-164.
56. Zolla-Pazner S. Identifying epitopes of HIV-1 that induce protective antibodies. Nat Rev Immunol 2004; 4: 199-210.
57. Coeffier E, Clement JM, Cussac; V, Khodaei-Boorane N, Jehanno M, Rojas M, et al. Antigenicity and immunogenicity of the HIV-1 gp41 epitope ELDKWA inserted into permissive sites of the MalE protein. Vaccine 2000; 19: 684-693.
58. Ofek G, Tang M, Sambor A, Katinger H, Mascola. JR, Wyatt R, et al. Structure and mechanistic analysis of the anti-human immunodeficiency virus type 1 antibody 2F5 in complex with its gp41 epitope. J Virol 2004; 78: 10724-10737.
59. Binley JM, Wrin T, Korber B, Zwick MB, Wang M, Chappey C, et al. Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies. J Virol 2004; 78: 13232-13252.
60. Agrawal L, Lu X, Jin Q, Alkhatib, G. Anti-HIV therapy: Current and future directions. Curr Pharm Des 2006; 12(16): 2031-55.
61. Bregenholt S, Jensen A, Lantto J, Hyldig S, Haurum JS. Recombinant human polyclonal antibodies: A new class of therapeutic antibodies against viral infections. Curr Pharm Des 2006; 12(16): 2007-15.
62. Markovic I. Advances in HIV-1 entry inhibitors: strategies to interfere with receptor and coreceptor engagement. Curt Pharm Des 2006; 12(9):1105-19.